Exagen Inc. (XGN)
Makes blood tests that help doctors diagnose lupus and other autoimmune diseases
$4.45+0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-48.4%
The outlook
XGN has strong analyst backing with a unanimous Strong Buy consensus, and the average price target sits roughly 93% above the current price. However, the stock is trading well below both its 50- and 200-day moving averages and sits near the lower end of its 52-week range, reflecting a downward price trend. The overall picture shows analyst optimism contrasting with recent weakness.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 7 analysts
Price trendBelow its 50- & 200-day averages
52-week range19% of the way from its 52-week low to high
Price targetAvg target +93% vs current price
Analyst price target
~12-month · 7 analysts$8.57average target+92.6% vs now
Now $4.45
Low $8.00High $10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$107.5M
52-wk high
$12.23
52-wk low
$2.59
50-day avg
$4.49
200-day avg
$5.36
Trailing P/E
—